Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez

UChicago Medicine Best of ASCO® 2024: NSCLC

UChicago Medicine Annual Practice Updates in Hematology and Oncology

R. Thawani

Options for Osimertinib-Resistant NSCLC

MI&T Congressi

T. Bivona

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

Biomarker Testing in aNSCLC: Current Guidelines, Gaps, and Impact on…

UChicago Medicine

R. Thawani

Biomarker Testing in NSCLC

Martin Dietrich

Key Metastatic NSCLC Trial Updates Including MARIPOSA and FLAURA2

Yale Cancer Center

S. Goldberg

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok

The Era of Precision Oncology

Springer Healthcare IME

J. Schneider

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

Patient Selection for Targeted Therapy in BRAF V600E NSCLC

Robert Hsu